Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma
Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS)…
Browsing Tag
Nivolumab
Determinants of Resistance to Nivolumab in Advanced Kidney Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, a study was presented…
Extra Follow-Up Confirms Benefit of Nivolumab in Muscle-Invasive Bladder Cancer
Longer-term follow-up of the CheckMate-274 trial confirmed that treatment with the anti-PD-1…
Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
Elana Gotkine
WEDNESDAY, Feb. 15, 2023 (HealthDay News) -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is…
Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous…
Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in…
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of…
What’s Left for Nivolumab to Prove in Stage IIIA NSCLC?
The addition of neoadjuvant nivolumab (Opdivo) to chemotherapy significantly improved outcomes in patients…
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a…
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in…
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at…
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination…
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11…
Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa’s autologous CD30-CAR-T therapy, is also being investigated as a monotherapy in…